Cigna (CI) Stock Forecast & Price Target

Cigna Group is well positioned because its earnings base is increasingly anchored in higher-margin specialty pharmacy and integrated benefits, where Evernorth’s Specialty and Care Services already supports more than 1 million complex-condition patients and is expected to grow 8.0% to 12.0% annually through 2030. Cigna Healthcare adds a second engine with 6.0% to 9.0% earnings growth through CY30, supported by a strong Select segment, 68.0% self-funded client mix, and the company’s broader employer-focused self-funding model. Even with the PBS transition to a Signature rebate-free structure and the planned 1/1/27 ACA Marketplace exit, management’s guidance implies visible adjusted EPS growth and at least $45.00 by CY30, reinforcing confidence in durable execution.

Cigna Group is facing a difficult earnings transition because its PBM business is moving from a rebate-driven model to Signature, which depends on customers accepting higher administrative fees while Evernorth margins have already been guided down from 3.5-4.5% to 3.0-3.5% for CY26. The company’s confidence in at least $30.45 adjusted EPS for CY26 and 10.0-14.0% adjusted EPS CAGR for CY26 to CY30 looks vulnerable if CY27 growth falls short, since that would force much stronger CY28-CY30 execution to reach the CY30 range. Despite attractive scale in a $300,000.0M specialty pharmacy market and $25,000.0M of expected CuraScript revenue in CY26, the outlook remains negative because pricing pressure, medical cost inflation, network contracting risk, and slower membership growth could all compress returns.